Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.
Shares quadrupled now that the company appears on track to reverse an earlier FDA rejection of what could be the first ...
Phase 3 data could make the Dutch biotech's drug competitive in the increasingly crowded market of hereditary angioedema treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback